Compare Amphastar Pharmaceuticals Inc (AMPH) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while GraniteShares 2x Long NVDA Daily ETF trades at $32.22. The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | NVDL | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $30.81 | $43.02 |
52-Week Low | $16.87 | $21.76 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $33.03, up 8.08% with a bullish technical signal. Recent stock splits (1:3 on June 25-26, 2026) reflect volatility management. The ETF has shown strong YTD performance (+12.66% as of June 8, 2026) but remains highly sensitive to NVIDIA's daily moves, evidenced by a 12% single-day drop on June 5, 2026. Technical indicators show bullish moving averages but neutral oscillators, with key resistance at $33.
Outlook: High-growth potential tied to NVIDIA's AI dominance, but leveraged structure amplifies risks. Daily resets can erode value during volatility, as seen in early 2025's 67% decline. Investors must weigh AI-driven upside against compounded losses in downtrends. Key risks include NVIDIA-specific volatility and broader semiconductor cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
